Clinical trials data
Symbol Coding in obesity and diabetes trials: 59 registered studies
Every registered obesity and diabetes study on ClinicalTrials.gov that names Symbol Coding in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered obesity and diabetes studies name it in an outcome measure
- 59
- Name it in a primary outcome, 46%
- 27 of 59
Tests named in the same studies
- 1
Trail Making Test26 studies, 13 as a primary outcome
- 2
Verbal Learning22 studies, 14 as a primary outcome
- 3
Digit Span Test17 studies, 11 as a primary outcome
- 4
Stroop Color-Word Test15 studies, 6 as a primary outcome
- 5
Verbal Fluency12 studies, 9 as a primary outcome
- 6
Category Fluency8 studies, 7 as a primary outcome
- 7
Short Story Recall5 studies, 2 as a primary outcome
- 8
Task Switching Test5 studies, 2 as a primary outcome
- 9
Letter-Number Sequencing Task4 studies, 3 as a primary outcome
- 10
Picture Naming Test4 studies, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 2 | 0 |
| 2010 | 3 | 2 |
| 2011 | 1 | 0 |
| 2012 | 1 | 0 |
| 2013 | 2 | 2 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 2 | 1 |
| 2017 | 1 | 1 |
| 2018 | 3 | 1 |
| 2019 | 5 | 1 |
| 2020 | 0 | 0 |
| 2021 | 4 | 2 |
| 2022 | 5 | 2 |
| 2023 | 6 | 3 |
| 2024 | 9 | 2 |
| 2025 | 5 | 4 |
| 2026 | 6 | 4 |
Phases and study sizes
By phase
- Early phase 11 studies, 0 as a primary outcome
- Phase 14 studies, 2 as a primary outcome
- Phase 22 studies, 1 as a primary outcome
- Phase 2/31 studies, 1 as a primary outcome
- Phase 31 studies, 0 as a primary outcome
- Phase 46 studies, 3 as a primary outcome
- Not applicable37 studies, 15 as a primary outcome
- Observational7 studies, 5 as a primary outcome
Participants per study
- Not applicable40 median, 20 to 99
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Not applicable | 37 | 40 | 20 to 99 |
When obesity and diabetes trials measure it
Latest time point of each outcome
- Within a day14 outcomes, 8 as a primary outcome
- Up to 4 weeks7 outcomes, 2 as a primary outcome
- 1 to 3 months8 outcomes, 5 as a primary outcome
- 3 to 6 months12 outcomes, 4 as a primary outcome
- 6 to 12 months7 outcomes, 3 as a primary outcome
- 1 to 2 years4 outcomes, 2 as a primary outcome
- Over 2 years4 outcomes, 1 as a primary outcome
- No duration given3 outcomes, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
56 of the 59 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting8 studies, 6 as a primary outcome
- Not yet recruiting3 studies, 0 as a primary outcome
- Active, not recruiting5 studies, 3 as a primary outcome
- Completed35 studies, 16 as a primary outcome
- Stopped early3 studies, 2 as a primary outcome
- Status unknown5 studies, 0 as a primary outcome
What they test
- Behavioral13 studies, 7 as a primary outcome
- Drug15 studies, 7 as a primary outcome
- Device5 studies, 1 as a primary outcome
- Dietary supplement13 studies, 4 as a primary outcome
- Procedure2 studies, 0 as a primary outcome
- Biological1 studies, 0 as a primary outcome
- Radiation1 studies, 0 as a primary outcome
- Other21 studies, 11 as a primary outcome
- None given4 studies, 3 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States22 studies, 13 as a primary outcome
- Denmark9 studies, 4 as a primary outcome
- Canada7 studies, 1 as a primary outcome
- China4 studies, 3 as a primary outcome
- United Kingdom4 studies, 0 as a primary outcome
- France2 studies, 1 as a primary outcome
- Germany2 studies, 1 as a primary outcome
- Italy2 studies, 0 as a primary outcome
- Mexico2 studies, 1 as a primary outcome
- Norway2 studies, 0 as a primary outcome
- Sweden2 studies, 0 as a primary outcome
- Switzerland2 studies, 0 as a primary outcome
36 countries in all. A study with sites in several counts in each; 0 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed obesity and diabetes studies that name Symbol Coding: 17 of 35, 49%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed obesity and diabetes studies that name Symbol Coding | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 4, 11% | 776, 10% |
| Results on ClinicalTrials.gov only | 7, 20% | 1,139, 14% |
| A results paper only | 6, 17% | 1,711, 22% |
| Neither | 18, 51% | 4,327, 54% |
The 59 studies
59 studies match. 27 name Symbol Coding in a primary outcome. Median size 66 participants. Median time to the primary outcome: 12 weeks.
Loading 59 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 that started before 2000.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 2 | 0 |
| 2010 | 3 | 2 |
| 2011 | 1 | 0 |
| 2012 | 1 | 0 |
| 2013 | 2 | 2 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 2 | 1 |
| 2017 | 1 | 1 |
| 2018 | 3 | 1 |
| 2019 | 5 | 1 |
| 2020 | 0 | 0 |
| 2021 | 4 | 2 |
| 2022 | 5 | 2 |
| 2023 | 6 | 3 |
| 2024 | 9 | 2 |
| 2025 | 5 | 4 |
| 2026 | 6 | 4 |
Library tests named most
Conditions
Phases
Participants
Lead sponsor: industry 4, NIH 2, other 53. Interventional 52, observational 7.
As a primary outcomeSecondary or other outcomeSymbol Coding
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07870291 | Start2026 | PhaseNot applicable | ConditionsObesity and diabetes | Participants105 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07750223 | Start2026 | PhaseNot applicable | ConditionsObesity and diabetes | Participants105 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07704229 | Start2026 | PhaseObservational | ConditionsObesity and diabetes | Participants150 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07694596 | Start2026 | PhaseNot applicable | ConditionsObesity and diabetes | Participants200 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07485062 | Start2026 | PhasePhase 4 | ConditionsAging, frailty and exercise, Obesity and diabetes | Participants164 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07420699 | Start2023 | PhaseNot applicable | ConditionsObesity and diabetes | Participants40 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07374705 | Start2026 | PhaseObservational | ConditionsObesity and diabetes | Participants150 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07284316 | Start2025 | PhasePhase 2/3 | ConditionsObesity and diabetes | Participants100 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07118904 | Start2025 | PhaseNot applicable | ConditionsObesity and diabetes, Sleep and sleep disorders | Participants12 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07040748 | Start2025 | PhaseNot applicable | ConditionsObesity and diabetes | Participants84 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06960941 | Start2025 | PhaseNot applicable | ConditionsObesity and diabetes | Participants24 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06912321 | Start2024 | PhaseObservational | ConditionsObesity and diabetes | Participants400 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06857994 | Start2025 | PhaseObservational | ConditionsObesity and diabetes, Cardiovascular disease | Participants101 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06624462 | Start2023 | PhaseNot applicable | ConditionsSchizophrenia and psychosis, Depression and bipolar disorder, Obesity and diabetes | Participants84 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06524388 | Start2024 | PhaseNot applicable | ConditionsAging, frailty and exercise, Obesity and diabetes | Participants120 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06496412 | Start2024 | PhaseNot applicable | ConditionsObesity and diabetes | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06260254 | Start2024 | PhaseNot applicable | ConditionsObesity and diabetes, Sleep and sleep disorders | Participants23 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06251635 | Start2024 | PhaseNot applicable | ConditionsSchizophrenia and psychosis, Obesity and diabetes | Participants15 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT06243172 | Start2024 | PhaseObservational | ConditionsObesity and diabetes, Sleep and sleep disorders | Participants60 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06242535 | Start2023 | PhaseEarly phase 1 | ConditionsDepression and bipolar disorder, Aging, frailty and exercise, Obesity and diabetes, Cardiovascular disease | Participants13 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT06236256 | Start2024 | PhaseNot applicable | ConditionsAging, frailty and exercise, Obesity and diabetes | Participants42 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06223204 | Start2024 | PhaseNot applicable | ConditionsObesity and diabetes | Participants16 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06122441 | Start2024 | PhaseNot applicable | ConditionsObesity and diabetes | Participants119 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT05997316 | Start2023 | PhaseNot applicable | ConditionsMild cognitive impairment, Obesity and diabetes | Participants33 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05794009 | Start2022 | PhaseNot applicable | ConditionsAging, frailty and exercise, Obesity and diabetes | Participants124 | Lead sponsorOther | StatusCompleted | Library tests named
|
Questions, answered from the data
How many obesity and diabetes trials use Symbol Coding?
59 registered obesity and diabetes studies on ClinicalTrials.gov name it in an outcome measure, 27 of them in a primary outcome: 9% of the condition's 627 studies with a cognitive outcome, against 9% of all of them. It is the 6th most named test in obesity and diabetes trials.
Which tests do obesity and diabetes trials use with Symbol Coding?
The Trail Making Test (26 studies), Verbal Learning (22 studies) and the Digit Span Test (17 studies).
When do obesity and diabetes trials measure Symbol Coding?
Half of the primary outcomes that name Symbol Coding are measured within 12 weeks of the start, and the middle half from the first day to 6 months. 25 primary outcomes give a duration.
How many completed obesity and diabetes trials that use Symbol Coding have reported results?
17 of the 35 completed studies that name it, 49%, have reported results: 11 posted them on ClinicalTrials.gov, 10 have a results paper linked to the registry record, and 4 did both. The other 18 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
The census counts Symbol Key Game and Symbol Coding as one test family, so this page counts their studies together.
Run Symbol Coding in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.